More articles from Volume 46, Issue 3, 2017
Randomization techniques in protocols for cluster randomized trials
Systematic review of factor validity of psychiatric scales in longitudinal studies
Comparison of clinical, biochemical and morphological parameters in patients with chronic hepatitis B
Impact of ocular comorbidities on visual function and quality of life in cataract and pseudophakic patients
Effects of different doses of zinc gluconate on antioxidative activity of metformin and glibenclamide on experimentally induced diabetes in rabbits
The problems associated with the treatment of chronic hyperuricaemia in Serbia
,
Milos Milosavljevic
Milica Milosavljevic
Abstract
Keywords
References
1.
Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2016;(5):983–92.
2.
Bernal J, Quilis N, Andrés M, Sivera F, Pascual E. Gout: optimizing treatment to achieve a disease cure. Ther Adv Chronic Dis. 2016;(2):135–44.
3.
Ankli B, Krähenbühl S.
4.
Ther Umsch. 2016;(3):115–24.
5.
Janković S. 2007;
6.
Gröbner W.
7.
Dtsch Med Wochenschr. 2015;(21):1615–26.
8.
Kasper I, Juriga M, Giurini J, Shmerling R. Treatment of tophaceous gout: When medication is not enough. Semin Arthritis Rheum. 2016;(6):669–74.
9.
Merriman T. An update on the genetic architecture of hyperuricemia and gout. Arthritis Res Ther. 2015;98.
10.
Desideri G, Castaldo G, Lombardi A. Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci. 2014;(9):1295–306.
11.
Choi H, Atkinson K, Karlson E, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;(7):742–8.
12.
Choi J, Ford E, Gao X, Choi H. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;(1):109–16.
13.
Tzeng H, Lin C, Wang I, Huang P, Tsai C. Gout increases risk of fracture: A nationwide population-based cohort study. Medicine. 2016;(34):4669.
14.
Chuang S, Chen J, Yeh W, Wu C, Pan W. Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort. Int J Cardiol. 2012;(3):316–21.
15.
Reuss-Borst M. When and how to treat? Internist (Berl). 2016;(2):194–201.
16.
Dalbeth N, Merriman T, Stamp L, Gout. Lancet. 2016;(16):346–9.
17.
Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Semin Arthritis Rheum. 2016;(16):30147–30147.
18.
Nickolai B, Kiss C.
19.
Ther Umsch. 2016;(3):153–8.
20.
Zhang Y, Neogi T, Chen C, Chaisson C, Hunter D, Choi H. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 2012;(12):4004–11.
21.
Bray G. Fructose and risk of cardiometabolic disease. Curr Atheroscler Rep. 2012;(6):570–8.
22.
Burns C, Wortmann R. Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis. 2012;(6):271–86.
23.
Pillinger M, Keenan R. Update on the management of hyperuricemia and gout. Bull NYU Hosp Jt Dis. 2008;(3):231–9.
24.
Republička stručna komisija za izradu I implementaciju vodiča dobre kliničke prakse. Ministarstvo zdravlja Republike Srbije. Nacionalni vodič dobre kliničke prakse za dijagnostikovanje I lečenje gihta. 2013;
25.
Reinders M, Haagsma C, Jansen T. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;(6):892–7.
26.
Chinchilla S, Urionaguena I, Perez-Ruiz F. Febuxostat for the chronic management of hyperuricemia in patients with gout. Expert Rev Clin Pharmacol. 2016;(5):665–73.
27.
Araujo E, Bayat S, Petsch C. Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD Open. 2015;(1):75.
28.
Hussar D, Gandhi M, Eluxadoline, Lesinurad, Idarucizumab. Am Pharm Assoc. 2003;(3):343–6.
29.
Republički fond za zdravstveno osiguranje. Lista A. Lekovi koji se propisuju I izdaju na obrascu lekarskog recepta.
30.
Agencija za lekove I medicinska sredstva. Alopurinol-Sažetak karakteristika leka.
31.
Stamp L, Day R, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016;(4):235–42.
32.
Wong A, Malvestiti A. Hafner Mde F. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review. Rev Assoc Med Bras. 1992;(5):468–73.
33.
Uloric (febuxostat) tablet for oral use-HIGHLIGHTS OF PRESCRIBING INFORMATION.
34.
Luo Z, Nan F, Miao J, Chen Z, Li M, Liang M. Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male Volunteers. PLoS One. 2016;(3):150661.
35.
Sattui S, Gaffo A. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;(4):145–59.
36.
Becker M, Schumacher H, Espinoza L. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;(2):63.
37.
Schumacher Hr, Becker M, Wortmann R. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;(11):1540–8.
38.
Kataoka H, Yang K, Rock K. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung. Eur J Pharmacol. 2015;174–9.
39.
Tsuruta Y, Mochizuki T, Moriyama T. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin Rheumatol. 2014;(11):1643–8.
40.
Gandhi P, Gentry W, Ma Q, Bottorff M. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. J Manag Care Spec Pharm. 2015;(2):165–75.
41.
Singh J, Akhras K, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015;120.
42.
Wells A, Macdonald P, Chefo S, Jackson R. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord. 2012;15.
43.
Becker M, Macdonald P, Hunt B, Jackson R. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013;(11):1049–55.
44.
Mitsuboshi S, Yamada H, Nagai K, Okajima H. Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients. J Pharm Health Care Sci. 2015;28.
45.
Chen C, Lü J, Yao Q. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Med Sci Monit. 2016;2501–12.
46.
Frampton J. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs. 2015;(4):427–38.
47.
Perez-Ruiz F, Díaz-Torné C, Carcedo D. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. J Med Econ. 2016;(6):604–10.
48.
Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;456–9.
49.
Harrold L, Andrade S, Briesacher B. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;R46.
50.
Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice:a qualitative study. Ann Rheum Dis. 2012;1490–5.
51.
Doherty M, Bardin T, Pascual E. International survey on the diagnosis and management of gout. Ann Rheum Dis. 2007;1685–6.
52.
Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately:proof-of-concept observational study. Ann Rheum Dis. 2013;826–30.
53.
Becker M, Schumacher H, Jr, Wortmann R. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;2450–61.
54.
Khanna D, Fitzgerald J, Khanna P. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;1431–46.
55.
Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014;(11):1920–6.
56.
Kim S, Schmidt B, Franklin J, Liu J, Solomon D, Schneeweiss S. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken). 2013;(12):2008–14.
57.
Jansen T, Reinders M, Van Roon E, Brouwers J. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence. Clin Exp Rheumatol. 2004;(5):651.
58.
Drugs.com Probenecid Dostupno.
59.
Sundy J, Baraf H, Yood R. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;711–20.
60.
Fellner C. Pharmaceutical Approval Update. P T. 2016;(2):95–6.
61.
Fleischmann R, Kerr B, Yeh L. RDEA594-111 Study Group. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology(Oxford). 2014;(12):2167–74.
62.
Shen Z, Rowlings C, Kerr B. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des Devel Ther. 2015;3423–34.
63.
Zurampic® (lesinurad) tablets, for oral use-HIGHLIGHTS OF PRESCRIBING INFORMATION.
64.
Perez-Ruiz F, Sundy J, Miner J, Cravets M, Storgard C. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;(6):1074–80.
65.
Saag KG, Fitz‐Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study). Arthritis & Rheumatology. 2016;69(1):203–12.
66.
Hoy S. Lesinurad: First Global Approval. Drugs. 2016;(4):509–16.
67.
Miloš TPAWTTOCHIS, Milosavljević N. Milica N Milosavljević 2 1 Faculty of Medical Sciences.
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
